Caligan Partners’s LB Pharmaceuticals LBRX Stock Holding History

Caligan Partners’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.7M	Hold	1,438,070	–	–	2.2%	11
2026 Q1	$34.6M	Buy	+1,438,070	New	+$33.2M	2.3%	13

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners's LBRX Position: Q2 2026 in Review

Caligan Partners held its LB Pharmaceuticals (LBRX) position steady in Q2 2026 at 1,438,070 shares worth $46.7M. The position accounts for 2.2% of the portfolio, ranked #11.

Caligan Partners first reported a position in LBRX in Q1 2026 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

Caligan Partners held 1,438,070 shares of LB Pharmaceuticals worth $46.7M as of Q2 2026.
Caligan Partners left its LB Pharmaceuticals share count unchanged in Q2 2026.
LB Pharmaceuticals made up 2.2% of Caligan Partners's portfolio in Q2 2026, its #11 holding.
Caligan Partners first reported a position in LB Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.